Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW 2009 Budget Requests ¥1.4 Billion To Strengthen PDMA Safety Measures

This article was originally published in PharmAsia News

Executive Summary

The Ministry of Health, Labor and Welfare released Aug. 26 a budget request for fiscal year 2009 of ¥22.85 trillion, an ¥829.2 billion and 3.8 percent increase compared to FY 2008's initial budget. The budget allocates ¥48.2 billion to stock up on flu drugs such as Tamiflu (oseltamivir)and Relenza (zanamavir) and pre-pandemic vaccines, and to develop pandemic vaccines. ¥33.2 billion is designated to develop new drugs in the areas of cancer, mental disorder, intractable and rare diseases and regenerative medicine. To boost safety measures in drugs and medical devices, ¥1.4 billion is allocated to the Pharmaceutical and Medical Device Agency to increase staff, and ¥900 million to the PDMA in establishing a consulting system to promote Japan-U.S.-Europe joint clinical trials and concurrent reviews for medical device. (Click here for more - Japanese language

You may also be interested in...



Japan’s MHLW Seeks 21% Budget Increase For Innovative Drugs

TOKYO - Japan's Ministry of Health Labor and Welfare is seeking a hefty 21 percent increase for developing innovative drugs and medical devices, according to its fiscal 2009 budget request submitted in late August

QUOTED. 24 February 2020. Daniel Taddeo.

Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.

Herbalife 'Just Getting Started' On Growth Following Flat 2019 At $4.9bn Net Sales

"We're a growth company, well-positioned in a global trend of nutrition that the world hasn't seen before," says co-president John Agwunobi. But the direct seller's record volume increase in 2019 didn’t translate to revenue growth as China, Mexico and Central and South America pulled down results.
UsernamePublicRestriction

Register

SC069391

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel